SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is surging as investors react to a strengthened partnership with NVIDIA, which positions the QNX operating system as a foundational element for mission-critical edge AI infrastructure across robotics, medical devices, and industrial automation. The community is actively discussing the stock's potential for a significant revaluation, with many long-term investors pointing to strong QNX growth and an expanded backlog as evidence that the companys turnaround is complete.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is trending due to its pivot toward critical infrastructure roles, specifically focusing on post-quantum security, native privacy, and the growth of its BTCFi ecosystem. The community remains highly engaged with the project's consistent developer activity and the expansion of its Layer-2 capabilities, viewing the current market price as a disconnect from its long-term technical value.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing a massive, parabolic short squeeze driven by a unique market structure where two major institutional holders effectively control the entire float. The community is actively debating the sustainability of this rally, with many calling it the largest squeeze since GameStop, while cautious traders warn of a potential crash once the company initiates a secondary offering to pay down its significant debt.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines is attracting significant market attention following a robust earnings report and successful labor negotiations, even as the sector faces near-term volatility from severe winter weather disruptions and shifting fuel cost projections. While investors weigh these operational headwinds against the company's strong bookings and premium travel demand, the community remains actively divided between those betting on a value-driven recovery and others concerned about the impact of capacity adjustments and broader geopolitical risks.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is trending as speculative traders engage in intense battles between long positions and short sellers, with the community actively debating the ticker's massive volatility, aggressive intraday price swings, and its classification alongside other low-float Chinese assets. The stock remains a focal point for investors searching for explosive breakouts, despite persistent community warnings about pump-and-dump mechanics and the asset's history of extreme price swings.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending as retail investors rally behind structural catalysts, specifically the recent termination of a dilution-heavy equity facility and the SEC's removal of pattern day trading restrictions. The community is actively debating potential for a short squeeze and price re-rating, comparing its valuation and platform growth to competitors like Robinhood.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently capturing market attention as investors pivot toward its proprietary polymer technology, which is being viewed as a potential game-changer for high-speed AI data centers. The community is buzzing over ongoing foundry integrations and speculative talk of upcoming tape-out results, fueling intense debate regarding whether the stock is a high-upside infrastructure play or an overextended speculative bubble.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AVEX is gaining significant momentum following its strong NYSE debut as investors pile into the defense technology sector, driven by heightened demand for autonomous drone systems and surveillance platforms. The community is actively discussing the stock's impressive post-IPO performance, comparing its growth potential and backlog visibility to established defense peers while closely monitoring the impact of ongoing geopolitical tensions on future contract awards.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased investor optimism following a larger-than-expected Medicare Advantage payment rate increase from CMS, which investors view as a de-risking catalyst for the sector. While some market participants are wary of volatility leading into the upcoming quarterly report, the community is actively debating the stock's ability to maintain these gains as institutions weigh regulatory clarity against long-term margin recovery targets.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is experiencing a significant surge following the release of positive Phase 3 clinical trial results for its psilocybin treatment, combined with broader market excitement surrounding a new executive order to accelerate psychedelic research. Investors are actively debating the company's valuation and potential for M&A as the community weighs the regulatory tailwinds against the recent announcement of a public offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Increases By 34.6%

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 9,878,573 shares, a growth...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat...

<ul class="summary-bullets"><li>Hemmati served as Capricor’s vice president of medical and clinical development for new therapies between 2015 and 2017.</li><li>Capricor is awaiting an FDA decision on its DMD therapy, Deramiocel, expected by Aug. 22.</li><li>The FDA resumed review last month after issuing a Complete Response Letter in July 2025, requesting additional clinical data.</li></ul>Shares of Capricor Therapeutics (CAPR) jumped 1% in premarket trading on Tuesday after reports said a former company executive is being considered to lead the FDA’s top gene therapy division just months before a key approval decision on its Duchenne muscular dystrophy (DMD) treatment.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> jumped 11% on Monday to end at $34.54, logging its best session in nearly two months.<h2 class="st-heading-2">Former Capricor Executive Emerges As FDA Biologics Chief Candidate</h2>Houman Hemmati, who served as vice president of medical and clinical development for new therapies at Capricor between 2015 and 2017, is among the candidates being interviewed by FDA Commissioner Marty Makary to head the Center for Biologics Evaluation and Research, or CBER, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-13/eye-doctor-considered-for-fda-vaccine-post-is-a-fox-news-regular">reported</a>.The division oversees approvals of vaccines and advanced gene and cell therapies, including treatments for rare diseases such as DMD. However, HHS spokesperson Andrew Nixon reportedly said no selection has been finalized and that the agency is still evaluating candidates.<h2 class="st-heading-2">CAPR Awaits Key FDA Ruling On DMD Therapy</h2>The development comes as Capricor awaits an FDA decision on Deramiocel, its investigational therapy for DMD, a rare genetic condition that causes progressive muscle weakness in children, expected by Aug. 22.The FDA resumed review of Deramiocel last month after issuing a Complete Response Letter (CRL) in July 2025, which indicated earlier that the agency could not approve the drug in its current form and typically requests additional data. Capricor’s resubmission included Phase 3 Hope-3 trial results showing 54% slower deterioration in upper-limb function and 91% slowing of cardiac disease progression, both statistically significant compared with placebo.Deramiocel consists of donor-derived cardiac cells, which reduces inflammation linked to muscle degeneration in DMD.<h2 class="st-heading-2">Prasad Exit Seen As Positive For Biotech Approvals</h2>The CBER leadership opening follows the departure this month of outgoing director Vinay Prasad, whose tenure drew criticism from the biotech industry over regulatory decisions affecting rare-disease therapies.Prasad’s exit news lifted several biotech stocks last month, with BMO Capital Markets calling the change “a sigh of relief” for the sector and saying it could improve approval prospects for multiple companies developing advanced therapies.During his tenure, Prasad was involved in disputes with companies, including Sarepta Therapeutics, over gene-therapy reviews and disagreements with UniQure and Regenxbio. He also briefly stepped away from the agency last year amid political criticism over regulatory decisions before returning weeks later with Makary’s support.<h2 class="st-heading-2">How Do Retail Traders Feel About CAPR?</h2>On Stocktwits, retail sentiment for CAPR jumped to ‘bullish’ from ‘bearish’ levels over the past day amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_26c2d1b5ac.webp" alt="capr ss.png" width="963" height="149"><figcaption>CAPR sentiment and message volume as of April 14 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/graywolf/message/650157552">said</a>, “$45-50 is my guess if the appointment is confirmed. 75+ upon approval, and $100+ with sale numbers,” referring to the prospects of Hemmati leading the CBER.<stembedurl>https://stocktwits.com/graywolf/message/650157552</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/WBinthehouse/message/650152118">said</a>, “if Dr Hemmati gets appointed as CBER chief, Vinay Prasad is gonna want credit for CAPRs approval. Will beat David to the punch. Guaranteed! Lol”<stembedurl>https://stocktwits.com/WBinthehouse/message/650152118</stembedurl>CAPR stock has jumped over 270% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-killers-musk-taunts-rivals-after-q1-us-deliveries-top-ev-market/cZJpx1BRIHE">'What Happened To All The Tesla Killers?' Elon Musk Taunts Rivals As Q1 US Deliveries Beat Every Other EV Maker Combined</a>

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision

Outgoing CBER director Vinay Prasad will depart this month, boosting approval prospects for several rare-disease therapies.

Equity

Capricor Therapeutics (NASDAQ:CAPR) Shares Up 9.7% - Should You Buy?

Capricor Therapeutics (NASDAQ:CAPR) Trading Up 9.7% - Should You Buy...

JPMorgan Chase & Co. Decreases Stock Position in Capricor Therapeutics, Inc. $CAPR

JPMorgan Chase & Co. reduced its position in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 45.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 189,799 shares of the biotechnology company's stock af...

Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells 7,529 Shares of Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) Director Karimah Es Sabar sold 7,529 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold...

Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 25,000 Shares

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) CFO Anthony Bergmann sold 25,000 shares of the company's stock in a transaction on Tuesday, March 31st. The stock was sold at an average...

Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6% - Here's Why

Capricor Therapeutics (NASDAQ:CAPR) Shares Up 6.6% - Still a Buy...

Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) Director Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $31.03, for a total value of $1,667,397.05. The transaction was...

Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) Director Karimah Es Sabar sold 61,265 shares of the business's stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The transaction was disclosed in a...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CAPR News

CAPRCapricor Therapeutics Inc